Neuron Loss in Transgenic Mouse Models of Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Since their initial generation in the mid 1990s, transgenic mouse models of Alzheimers's disease (AD) have been proven to be valuable model systems which are indispensable for modern AD research. Whereas most of these models are characterized by extensive amyloid plaque pathology, inflammatory changes and often behavioral deficits, modeling of neuron loss was much less successful. The present paper discusses the current achievements of modeling neuron loss in transgenic mouse models based on APP/Aβand Tau overexpression and provides an overview of currently available AD mouse models showing these pathological alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 2×
“These mice also show synaptic alterations demonstrated by a decline in synaptophysin levels already at 4 months of age as well as significantly reduced syntaxin and PSD-95 levels at the age of 9 months [28].”
BackgroundAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“Alzheimer’s disease (AD) represents the most frequent form of dementia and is characterized by two major neuropathological hallmarks: (i) extracellular plaques composed of the 40–42 residues Aβ peptide [1] and (ii) neurofibrillary tangles (NFTs), consisting of abnormal phosphorylated Tau protein [2].”
BackgroundAlzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · cited 2×
“, PDAPP [7], Tg2576 [8], APP/Ld [9], TgCRND8 [10], APP23 [11], tg APP ArcSwe [12], APP-Au [13], or APPE693Δ [14]), bigenic mice expressing both APP and PS1/PS2 or Tau (e.”
BackgroundReducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · cited 1×
“Although it has been shown that reductions in Tau levels prevented behavioral deficits in transgenic mice expressing human amyloid precursor protein and also protected both transgenic and nontransgenic mice against excitotoxicity [47], overexpression of mutant Tau in APP or APP/PS transgenic mice does not result in dr…”
BackgroundTwo amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.040 · Cited by 1,294 · cited 1×
“Behavioral analyses have suggested that intracellular Aβ accumulation is functionally linked to cognitive impairment in these mice, as they develop deficits in long-term retention at the age of 4 months, a time point prior to plaque deposition where only intracellular Aβ is present [44].”
BackgroundBorchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (1997) · Neuron · doi:10.1016/s0896-6273(00)80974-5 · Cited by 1,023
Intraneuronal Aβ42 Accumulation in Human Brain
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991 · cited 1×
“There is increasing evidence that, in addition to the wellknown extracellular amyloid deposition in the parenchyma, Aβ peptides accumulate within neurons [3].”
BackgroundChishti, M. A., Yang, D.-S., Janus, C., Phinney, A. L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., French, J., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100710200 · Cited by 955 · cited 2×
“, PDAPP [7], Tg2576 [8], APP/Ld [9], TgCRND8 [10], APP23 [11], tg APP ArcSwe [12], APP-Au [13], or APPE693Δ [14]), bigenic mice expressing both APP and PS1/PS2 or Tau (e.”
BackgroundMoechars, D., Dewachter, I., Lorent, K., Reversé, D., Baekelandt, V., Naidu, A., Tesseur, I., Spittaels, K., Haute, C. V. D., Checler, F., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6483 · Cited by 668
IRIZARRY, M. C., MCNAMARA, M., FEDORCHAK, K., HSIAO, K., & HYMAN, B. T. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199709000-00002 · Cited by 649
Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T. A., & Wirths, O. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.027 · Cited by 623 · cited 1×
“No reductions in neuron numbers and no intraneuronal Aβ immunoreactivity were detected in the CA1 layer of the hippocampus adding further evidence to the assumption that intraneuronal Aβ accumulation is closely associated with neuron loss [37].”
BackgroundSelf-citationSaido, T. C., Iwatsubo, T., Mann, D. M. A., Shimada, H., Ihara, Y., & Kawashima, S. (1995) · Neuron · doi:10.1016/0896-6273(95)90301-1 · Cited by 587 · cited 1×
“One of the most abundant truncated peptides in AD brain is AβpE3–42 carrying a pyroglutamate (pE) at position 3 [38].”
BackgroundThe Alzheimer's Aβ peptide induces neurodegeneration and apoptotic cell death in transgenic mice
LaFerla, F. M., Tinkle, B. T., Bieberich, C. J., Haudenschild, C. C., & Jay, G. (1995) · Nature Genetics · doi:10.1038/ng0195-21 · Cited by 513
Neuron loss in APP transgenic mice
Calhoun, M. E., Wiederhold, K.-H., Abramowski, D., Phinney, A. L., Probst, A., Sturchler-Pierrat, C., Staufenbiel, M., Sommer, B., & Jucker, M. (1998) · Nature · doi:10.1038/27351 · Cited by 502 · cited 1×
“The number of CA1 neurons is inversely correlated with CA1 plaque load and neuron loss was observed primarily in the vicinity of extracellular plaques [25].”
BackgroundIrizarry, M. C., Soriano, F., McNamara, M., Page, K. J., Schenk, D., Games, D., & Hyman, B. T. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-18-07053.1997 · Cited by 497 · cited 1×
“Whereas most of these models present abundant extracellular amyloid plaque pathology, several efforts modelling significant neuron loss remained less successful [22, 23].”
BackgroundCasas, C., Sergeant, N., Itier, J.-M., Blanchard, V., Wirths, O., van der Kolk, N., Vingtdeux, V., van de Steeg, E., Ret, G., Canton, T., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63388-3 · Cited by 400
Self-citationTomiyama, T., Matsuyama, S., Iso, H., Umeda, T., Takuma, H., Ohnishi, K., Ishibashi, K., Teraoka, R., Sakama, N., Yamashita, T., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5825-09.2010 · Cited by 396 · cited 5×
“Very recently, a new transgenic mouse model expressing human APP with the APPE693Δ mutation has been published [14].”
BackgroundInfluentialBlanchard, V., Moussaoui, S., Czech, C., Touchet, N., Bonici, B., Planche, M., Canton, T., Jedidi, I., Gohin, M., Wirths, O., et al. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00252-8 · Cited by 283
Self-citationSchmitz, C., Rutten, B. P. F., Pielen, A., Schäfer, S., Wirths, O., Tremp, G., Czech, C., Blanchard, V., Multhaup, G., Rezaie, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63235-x · Cited by 281 · cited 1×
“This observation points to the potential involvement of more than one mechanism in hippocampal neuron loss in this mouse model [29].”
BackgroundSelf-citationOn the Seeding and Oligomerization of pGlu-Amyloid Peptides (in vitro)
Schilling, S., Lauber, T., Schaupp, M., Manhart, S., Scheel, E., Böhm, G., & Demuth, H.-U. (2006) · Biochemistry · doi:10.1021/bi0612667 · Cited by 254 · cited 1×
“It has been demonstrated that this peptide is characterized by a higher aggregation propensity [39], stability [40], and increased toxicity compared to fulllength Aβ [41].”
BackgroundUrbanc, B., Cruz, L., Le, R., Sanders, J., Ashe, K. H., Duff, K., Stanley, H. E., Irizarry, M. C., & Hyman, B. T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222433299 · Cited by 237
Wirths, O., Breyhan, H., Cynis, H., Schilling, S., Demuth, H.-U., & Bayer, T. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0557-5 · Cited by 174
Self-citationChristensen, D. Z., Kraus, S. L., Flohr, A., Cotel, M.-C., Wirths, O., & Bayer, T. A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0451-6 · Cited by 126 · cited 1×
“No neuron loss could be observed in the thalamus where on extracellular Aβ plaques, however, in a comparable amount as in the cortex were present [32].”
BackgroundSelf-citationHippocampal interneuron loss in an APP/PS1 double mutant mouse and in Alzheimer’s disease
Takahashi, H., Brasnjevic, I., Rutten, B. P. F., Van Der Kolk, N., Perl, D. P., Bouras, C., Steinbusch, H. W. M., Schmitz, C., Hof, P. R., & Dickstein, D. L. (2010) · Brain Structure and Function · doi:10.1007/s00429-010-0242-4 · Cited by 124 · cited 1×
“Interestingly, a significant loss of parvalbumin- (PV)-positive interneurons in CA1-2 (40%–50%) and calretinin- (CR)-immunoreactive interneurons in the hilus and dentate gyrus (37%–52%) has been recently reported in 10-month-old APP/PS1KI mice [34].”
BackgroundKuo, Y.-M., Webster, S., Emmerling, M. R., De Lima, N., & Roher, A. E. (1998) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(98)00014-3 · Cited by 122 · cited 1×
“It has been demonstrated that this peptide is characterized by a higher aggregation propensity [39], stability [40], and increased toxicity compared to fulllength Aβ [41].”
BackgroundPhosphorylation of Tau at S422 is enhanced by Aβ in TauPS2APP triple transgenic mice
Grueninger, F., Bohrmann, B., Czech, C., Ballard, T. M., Frey, J. R., Weidensteiner, C., von Kienlin, M., & Ozmen, L. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.09.004 · Cited by 117 · cited 1×
“Quantitative receptor autoradiography revealed significantly reduced mGluR2 levels in aged triple transgenic mice, which were however not different from the PS2APP double transgenic control line, arguing against a prominent role of increased Tau phosphorylation [46].”
BackgroundFaure, A., Verret, L., Bozon, B., El Tannir El Tayara, N., Ly, M., Kober, F., Dhenain, M., Rampon, C., & Delatour, B. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.03.009 · Cited by 112 · cited 1×
“This loss is likely due to local extracellular plaque pathology [26], in combination with a complete loss of neurogenesis already at the age of 6 months [35, 36], which prevents any re-integration of new-born neurons in that particular cell layer.”
BackgroundAPP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy
Breyhan, H., Wirths, O., Duan, K., Marcello, A., Rettig, J., & Bayer, T. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0539-7 · Cited by 87 · cited 1×
“In addition, recordings of field excitatory postsynaptic potentials (fEPSPs) revealed a significant reduction of 6 months in APP/PS1KI compared to PS1KI or nontransgenic mice [31].”
ResultSelf-citationChristensen, D. Z., Bayer, T. A., & Wirths, O. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.07.022 · Cited by 77 · cited 1×
“A related observation was made in distinct cholinergic brain stem nuclei (Mo5, 7N) in this mouse model, where neuronal loss at 6 or 12 months of age correlated with the presence of intraneuronal Aβ peptides [33].”
BackgroundSelf-citationBoncristiano, S., Calhoun, M. E., Howard, V., Bondolfi, L., Kaeser, S. A., Wiederhold, K.-H., Staufenbiel, M., & Jucker, M. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.06.010 · Cited by 68 · cited 1×
“Surprisingly, no differences in the neocortical synaptic bouton number as well as in synaptophysin protein levels were detected during aging or in comparison with agematched nontransgenic control mice [27].”
Background
Cited by
Wright, A. L., Zinn, R., Hohensinn, B., Konen, L. M., Beynon, S. B., Tan, R. P., Clark, I. A., Abdipranoto, A., & Vissel, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059586 · Cited by 313
Dionísio, P. A., Amaral, J. D., Ribeiro, M. F., Lo, A. C., D'Hooge, R., & Rodrigues, C. M. P. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.08.034 · Cited by 127
Rubio, S. E., Vega‐Flores, G., Martínez, A., Bosch, C., Pérez‐Mediavilla, A., Río, J. D., Gruart, A., Delgado‐García, J. M., Soriano, E., & Pascual, M. (2012) · The FASEB Journal · doi:10.1096/fj.12-208413 · Cited by 98
Hüttenrauch, M., Brauß, A., Kurdakova, A., Borgers, H., Klinker, F., Liebetanz, D., Salinas-Riester, G., Wiltfang, J., Klafki, H. W., & Wirths, O. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.65 · Cited by 78
“19 Therefore, hardly any research investigations have been performed to test the effect of physical activity on hippocampal neuron numbers in animal models using detailed, design-based quantitative techniques.”
Self-citationChun, H., Marriott, I., Lee, C. J., & Cho, H. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00797 · Cited by 77
Metadata
- Authors
- Wirths, O., & Bayer, T. A.
- Venue
- International Journal of Alzheimer's Disease
- Publisher
- Wiley
- Published
- 2010
- Volume
- 2010
- Pages
- 1-6
- ISSN
- 2090-0252 (ISSN-L)
- OpenAlex
- W1999717818
- Cited by
- 111
- References
- 33
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.